Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
United States
University of California, Irvine, Irvine, California University of California, Los Angeles, California University of California, San Francisco, San Francisco, California Yale University Conneticut Mental Health Center, New Haven, Connecticut Beth Israel Deaconess Medical Center, Boston, Massachusetts Washington University, St Louis, Missouri Northwell Health, Glen Oaks, New York Columbia University, New York, New York Icahan School of Medicine at Mount Sinai, New York, New York University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Ohio State University, Columbus, Ohio Prevention Science Institute, Eugene, Oregon University of Pennsylvania, Philadelphia, Pennsylvania Temple University, Philadelphia, Pennsylvania University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania